Investment Pitches

Pitch Summary:
The short thesis for MGP Ingredients was based on the anticipated downturn in the whiskey industry following a period of heightened demand driven by the pandemic. The company's operational performance has deteriorated, with declining revenue and profitability reflecting industry headwinds such as elevated inventories and reduced consumption.

BSD Analysis:
MGP Ingredients' reliance on the whiskey industry, which is facing a downturn, has led to a significant decline in its stock price. The company's revised guidance for 2025 suggests limited visibility into future contracts, exacerbating concerns about its operational outlook. Despite the Branded Spirits segment's resilience, the core Distilling Solutions business is under pressure. The whiskey industry is grappling with an oversupply issue, with inventories exceeding a decade's worth of consumption. This environment poses challenges for MGP Ingredients, as the company struggles to navigate the downturn. While the stock has already fallen significantly, further deterioration in the whiskey market could continue to impact MGP's performance.

Pitch Summary:
The author argues that Rapid Micro Biosystems ($RPID) is a deeply mispriced microcap growth compounder masquerading as a broken IPO. The company automates microbial quality control for biologics, cell/gene therapy, vaccines, and sterile injectables—replacing a fully manual process in a greenfield market with a razor-and-blade model. Shares trade around $2.80 despite a prior rejected $5 bid, ~3.5× 2025E sales, and what the author believes is a structurally understated growth profile (20–30% for several years). Recurring revenue exceeded 55% in 2024 and is inflecting sharply, with pull-through accelerating >20% QoQ, driving materially higher gross margins than consensus assumes. The author expects a guide-above setup as FY25 estimates imply decelerating growth and weaker margins despite cost discipline, rising consumables mix, and validation wins with Samsung Biologics and Lonza.

BSD Analysis:
The biologics manufacturing tools market is structurally attractive, defined by stringent regulatory requirements, long asset lives, and high switching costs once systems are validated. Within this industry structure, Rapid Micro holds a differentiated position by automating a mission-critical, labor-intensive process that scales directly with biologics volume growth. Secular tailwinds—cell and gene therapy expansion, sterile injectables, and increased regulatory scrutiny—support sustained demand independent of macro cycles. The competitive moat stems less from rivalry (manual methods remain the primary alternative) and more from workflow integration, validation inertia, and consumables pull-through. Key risks include execution during the margin inflection, customer capital-spend cyclicality for initial system placements, and balance-sheet sensitivity if growth underdelivers. Valuation reflects skepticism around near-term profitability rather than normalized earnings power; at maturity, a 25–30% operating margin profile on a high-recurring base would imply a dramatically higher earnings base. From a buy-side perspective, the asymmetry lies in whether RPID successfully transitions from “early-commercial” to “standard-of-care”—if it does, today’s multiple materially understates long-term earnings power.

Actual Post Content:
I'm a compounder bro at heart, but talking about $TMO $DHR can get boring, so here's a FUN topic, especially for the micro cap degenerates out there: - in my PA I have a naughty little micro cap called Rapid Micro Biosystems ( $RPID), or as I like to call it, RapidCoin. Have followed it at a distance since it went public (way too early) in 2021, but first buy was at the beginning of this year. Added some more at today's price because it's still cheap AF and I'm a strong independent man who don't need no compliance department. Company reports tomorrow morning, think it'll be a good time. Strap in: Trades at ~$2.80, refused a bid for $5 a while ago. Makes a lot of sense as a tuck-in for any tools/industrial co that wants more BP exposure once it stops looking like a POS in a screener. 2025 P/S is ~3.5x on consensus ests which are too low, growth is probably in the 20-30% range for next 5ish yrs, LT algo supports HSD-LDD% growth at maturity, peak op margin profile of 25-30% assuming GM of 60-65%. Company makes a system that automates microbial quality control which is needed for biologics/cell/gene/vaccine/sterile injectable manufacturing. Competes exclusively with doing it manually - total greenfield situation. Razor & blade model. Just above 55% recurring in 2024, peak was 64% when market froze for equipment adoption in 2022. I'd expect it to mix toward 70-80% over time. Consumable gross margins much higher than equipment (common). It's one of those management says they don't need financing but consensus numbers who they're cutting it awfully close and gross margins just turned positive" stories. Rev + GM trajectory are therefore 90% of what matters, unless they turn off the cost discipline they've implemented over the past year or so. Setup is great because we already have most of the info you need to support a sizeable guide-above. They gave a pre-A at JPM, which was 4Q revenue (w/ mix), but no PnL or FY25 guidance (these will be the incremental). Rev was >5% above in the Q. Both the non-rec and recurring halves grew q/q, but recurring pull-through ACCELERATED BY 22% (13% adj. for comps). Consensus numbers had 4Q rev growth decelerating (accelerated through a tough comp...), and gross margin of ~15%. A 5% rev beat will likely carry a much better GM since the beat was a mix toward recurring rev. Even if incrementals are the same as consensus, GM was almost 400bps better and GP was 32% above on the leverage. Based on this and developments of the last 14 months, FY25 consensus is RIDICULOUS. Assumes growth decelerates a lot and that RPID ADDS LESS $ REVENUE THAN IT DID LAST YEAR. Lol. Gross margin of 14.5% is lower than the stale 4Q24 estimate This is all despite cost control and another ~$5M of rev coming in, inflecting consumables, higher system ASPs. Counter argument to using the 4Q jump-off is seasonality, which is only relevant for the equipment half. This is offset by a new product launched in 2H and the fact that equipment revenue is definitely still growing in 2025. Either way, if you annualize 4Q pull-through on validated systems, you get 2/3s of the growth from recurring rev, without even assuming pull through gets better, which happens naturally as the % of validated systems that are new declines each year (not to mention pricing). You can get to consensus revenue with the above recurring rev + flat system placements and an ASP (7%) lower than 4Q. If you model revenue like an adult, it's hard to get a number that isn't 10%+ above consensus unless you think they stop selling boxes. That + using the same incremental gross margin old consensus had bridges you to gross profit coming in >40% above in 2025. Maybe management sandbags a bit, but the gap is so wide, who cares? Most of the permutations one can make w/ the assumptions produce revenue estimates that are above by so much that management could guide 9% above, to accelerating growth vs consensus decelerating, and still have room for beats/raises. They are also in year 2 of a partnership w/ Samsung Biologics, and just signed a module w/ Lonza which would represent a TON of demand without a single other customer getting added for 5 years. I cannot understate how strong of a technology signal it is to be a micro cap w/ a cash crunch that still signs these two. I'm excited, but I'm not the only one. CEO, CFO, and 2 board members all bought in 2H last year, albeit at lower prices. You still have a couple hours to join me. Otherwise, feel free to come back and roast me if this blows up in my face. Have fun!"

URL: https://x.com/borlaug_/status/1895178394091794755

Pitch Summary:
The author states that Digital Bros ($DIB.MI) no longer offers an attractive risk/reward after a ~50% share price appreciation since the original pitch. Expectations around the Assetto Corsa (AC) franchise have been tempered, with AC EVO requiring more development resources than initially assumed and early pricing coming in lower than expected. New titles such as Blades of Fire introduce execution risk given the challenging AA gaming market, while Crime Boss and Directorate: Novitiate have underperformed. Offsetting factors include a still-reasonable valuation range (author estimates €180–350m vs. ~€215m current market cap) and strong traction for Wuchang, albeit with revenues pushed into the next fiscal year. Overall, the author prefers to reallocate capital to other opportunities, noting the stock’s increased vulnerability to negative news after its sharp run-up.

BSD Analysis:
Mid-tier video game publishing is structurally volatile, with outcomes driven by hit economics, long development cycles, and lumpy release schedules rather than steady compounding. Digital Bros’ competitive position remains mixed: the AC franchise provides a valuable IP anchor, but limited studio scale constrains content velocity and franchise expansion versus larger peers. Secular demand for premium games persists, yet the AA segment faces heightened pressure from ballooning development costs and intense competition for player attention. The key risk is capital misallocation—continued investment in underperforming titles can erode returns despite headline revenue growth. Valuation is no longer distressed and now embeds some success from future releases, reducing margin of safety. While upside remains if Wuchang becomes a breakout and AC EVO stabilizes, earnings visibility is limited in the near term. From a buy-side lens, Digital Bros now looks more like a fair-value, option-driven publisher than a mispriced compounder, making relative opportunity cost the dominant consideration.

Actual Post Content:
$DIB.MI After 50% share price appreciation since my first pitch I think the risk-reward is not very attractive anymore. Please find my arguments in the AC EVO is OK, but needs a lot of work. resources are limited - there are < 30 employees at Kunos and it seems that less content is being added to AC and ACC. Also, ACE price was lower than I expected. All in all, I’ve been too optimistic with AC franchise expectations for FY25 2. Today the company revealed Blades of Fire - an action RPG by a renowned Spanish studio. The game will be likely good, but this is a tough market for AAs, so I see rather a risk here. Directorate: Novitate has a very weak traction so far: 4. Crime Boss is a disaster, curious how much of it they still have on their books… Counterarguments: 1. Valuation still not very demanding, even with lower AC forecast I see it in 180 - 350 range vs 215m mcap. 2. Wuchang has excellent and improving traction, but will likely be released next FY. All in all, I see better opportunities elsewhere. Also from trading perspective the stock appreciated a lot, which makes it more vulnerable to any potential bad news. Thank you for update. Do you see better opportunities now in gaming or somewhere else? Congrats on $DIB, and thanks for sharing this one - it massively outperformed every smaller gaming company I do follow. Thank you 🙏. I would say both, e.g. in gaming I like $ALDNE better, despite higher risk. I also think your $GUI idea is very nice and better than $DIB now. There are some things I like outside of gaming, plan to pitch them when I catch a breath 😉

URL: https://x.com/quackquackcap/status/1895232374906273880

Pitch Summary:
Alexander Wolf, a board member with a strong track record, is purchasing Appfolio stock for his personal accounts, indicating confidence in the company's future. The stock is currently experiencing a 20% drawdown, suggesting a potentially attractive entry point. Appfolio is recognized for its high-quality metrics, growing at high-teens percentages with over 25% margins. The company has a significant growth runway, making it an appealing investment in the VMS/SaaS sector.

BSD Analysis:
Appfolio's position as a leader in the VMS/SaaS space is reinforced by its robust financial performance and growth potential. The company's ability to maintain high margins while expanding its market share suggests operational efficiency and a competitive edge. The involvement of a board member like Alexander Wolf, who has a history of successful trades, adds credibility to the bullish outlook. Despite the current stock drawdown, the long-term growth prospects remain strong, supported by the company's strategic focus and market demand for its solutions.

Pitch Summary:
Bel Fuse is positioned for significant growth following its acquisition of Enercon Technologies, which enhances its presence in the aerospace and defense sectors. Despite recent challenges, including a decline in net sales due to industry headwinds and Chinese supplier issues, the company has demonstrated resilience with improved gross margins and a strong balance sheet. The anticipated recovery in its Magnetics and Power Solutions segments, coupled with strategic leadership changes and operational improvements, supports a bullish outlook. The stock is undervalued compared to peers, offering a potential 50% upside with a target price of $125, driven by projected revenue and EBITDA growth.

BSD Analysis:
Bel Fuse's strategic acquisition of Enercon Technologies is expected to contribute significantly to its top-line growth, particularly in the high-demand aerospace and defense markets. The company's focus on operational efficiencies, such as factory consolidation and enhanced procurement strategies, is likely to drive margin improvements. Despite current challenges in the consumer electronics segment and tariff-related risks, Bel Fuse's ability to pass costs to customers mitigates some of these pressures. The company's valuation, at 11.8x 2024 EV/EBITDA, remains attractive compared to peers like TE Connectivity and Littelfuse, which trade at higher multiples. With a strong cash generation capability and a leverage ratio of 2.3x post-Enercon acquisition, Bel Fuse is well-positioned to reduce debt and potentially resume share buybacks, further enhancing shareholder value. The anticipated leadership transition to Farouq Tuweiq as CEO is expected to sustain the company's strategic direction and capital allocation discipline, supporting its growth trajectory.

Pitch Summary:
The author argues that FTAI Aviation remains an attractive long despite a sharp rebound from recent lows following a short report that temporarily forced the stock to trade at a pure leasing multiple. The short thesis focused on dismissing FTAI’s Products segment as undifferentiated, driving shares from ~$180 to ~$80 before stabilizing. The presenter believes this de-risked the valuation and that the real upside now lies in FTAI’s Strategic Capital Initiative (SCI), which has already deployed ~$1bn of third-party capital YTD 2025. The plan is to scale this to $3–5bn annually, acquiring aircraft that will exclusively utilize FTAI’s engine maintenance network, effectively monetizing market share without balance-sheet strain. This SCI ramp, not embedded in consensus, could add ~$400m of incremental Products EBITDA by 2026 assuming ~$6bn cumulative deployment and PMA approval, implying ~30% upside to consensus and significant rerating potential. The presenter frames the risk/reward as asymmetric, estimating ~10% downside versus 80%+ upside.

BSD Analysis:
The aircraft engine aftermarket is structurally attractive, with long asset lives, regulatory barriers, and chronic supply constraints supporting pricing power for approved PMA parts and MRO services. FTAI’s competitive position is unusual in that it vertically integrates leasing, asset ownership, and aftermarket products, allowing it to influence engine routing and capture downstream economics. The Strategic Capital Initiative materially strengthens this position by using third-party capital to expand the installed base tied to FTAI’s maintenance ecosystem, a flywheel that peers cannot easily replicate. Secular tailwinds include aging global fleets, deferred OEM maintenance capacity, and airline cost pressure favoring PMA adoption. Key risks center on execution of the SCI, timing and certainty of PMA approvals, and potential regulatory or OEM pushback. Valuation today implies skepticism that FTAI’s Products business can sustain differentiated margins; however, if SCI-driven volume materializes, earnings power could scale non-linearly. From a buy-side perspective, the stock’s optionality stems from capital-light growth layered on top of an already cash-generative core, making the asymmetry credible even after the rebound.

Actual Post Content:
$FTAI long pitch from MCH idea dinner Copy and pasted below For background, there was a short report issued a few weeks ago. The stock went from $182 to $80 at the bottom (the stock touched $76 intra-day). The short report essentially went after the company’s products business, and said that it was not doing differentiated work, and that it deserved a leasing multiple. The stock subsequently traded down to $80 per share (it derated to a leasing multiple on consensus numbers). From here, the presenter believes the easy money has been made, but the real moving piece is the company’s new strategic capital initiative that has already deployed $1 billion YTD in 2025 (using third-party capital). They have bought aircraft both from within FTAI, as well as externally already. The presenter thinks the plan is to deploy $3 to $5 billion per year to buy aircraft that will only be using FTAI’s maintenance network for these engines, essentially using third-party capital to add market share. None of this is currently in consensus numbers. If you assume $6 billion of deployment cumulatively in 2025 and 2026, this could add $400 million of Products EBITDA by 2026 incorporating PMA, which would drive 30% upside versus current consensus estimates for Products EBITDA. If you believe in the SCI ramp and PMA approval, the stock remains cheap even after this recent move higher. Without PMA approval, the implied Products multiple is 14x today (versus peers at 16-18x). If you assume PMA actually occurs, then the implied multiple of the Products business is 12x. The presenter believes the upside here is that the stock rerates 6x to a typical aftermarket multiple. In terms of the risk/reward, the presenter believes it is down 10% to up 80% at the minimum. Even after this run up in the stock, you are playing an asymmetric risk/reward profile.

URL: https://x.com/KryptoniteRese/status/1894776103274762465

Pitch Summary:
The main app is based on 'Ad Fraud'; data steal from Meta; exploiting customers on Google and Apple, violating app store policies; serving sex ads to kids; likely to be kicked out of app stores;

BSD Analysis:
AppLovin operates in mobile adtech and game distribution. The short thesis highlights dependency on user acquisition spending, regulatory risk from privacy changes (Apple ATT), and intense competition from Unity and global ad networks. While AppLovin has shifted strategy toward software revenue, the balance sheet carries leverage from past acquisitions. Without sustained growth in software platform margins, the equity may re-rate lower.

Pitch Summary:
The single largest US stock promotion; silent, back-door app installation that is largely fraudulent; tricking META users into inserting its ads on the platform. Update 6/12/25 - Installs third party apps without consent; misleading AI claims for marketing hype; inflated and manipulated ad metrics and performance; CEO's past involvement with spyware companies; shares dropped over 15%, losing nearly $17 billion in value.

BSD Analysis:
Communication Services

Pitch Summary:
Grab Holdings Limited is positioned to capitalize on the growing demand for integrated digital services in Southeast Asia. With a diverse portfolio spanning ride-hailing, food delivery, and financial services, the company is set to benefit from increasing user adoption and enhanced monetization strategies. The strategic partnership with BYD to expand its EV fleet further strengthens its competitive edge in the region. Despite current profitability challenges, Grab's path to breakeven is clear, supported by improving operating margins and a robust cash position.

BSD Analysis:
Grab's strategic initiatives, such as the acquisition of Uber's Southeast Asia operations and the formation of GXS Bank with Singtel, have fortified its market position. The company's focus on expanding its EV fleet through a partnership with BYD aligns with global sustainability trends and could enhance its appeal to environmentally conscious consumers. Grab's dual-class share structure, while ensuring control for founder Anthony Tan, may warrant a valuation discount due to governance concerns. However, its strong cash reserves and lack of debt provide financial flexibility for future acquisitions or strategic investments. The company's ability to quadruple revenue hinges on successful user growth and monetization, particularly through high-margin segments like GrabMaps and GrabAds. As Southeast Asia's digital economy continues to expand, Grab is well-positioned to emerge as a dominant player, akin to Uber's trajectory in the U.S. market.

Pitch Summary:
KULR Technology Group is portrayed as a company with questionable business practices and financial health. Despite claiming expertise in energy storage and thermal management, the company's financials reveal a concerning picture with significant cash burn and minimal cash reserves. The company has been issuing equity aggressively to stay afloat, and its recent pivot to a 'Bitcoin Treasury' strategy appears to be a stock promotion tactic. The management's surprise at the stock's run-up to $5 suggests a lack of confidence in their own strategy. The company's reliance on equity issuance to fund operations is unsustainable, and the narrative is likely to collapse, leading to a significant decline in stock value.

BSD Analysis:
KULR's financial metrics indicate a company struggling to maintain viability, with a low R&D expenditure and a small number of patents, suggesting it is not at the forefront of innovation in its industry. The company's decision to increase its ATM offering and pursue a Bitcoin strategy raises red flags about its long-term business model. The involvement of related parties and the questionable background of its CFO further undermine confidence in the company's governance. Given these factors, the stock appears overvalued, and the ongoing dilution of shares will likely erode shareholder value. Investors should be cautious of the speculative nature of KULR's business and the potential for significant downside risk.

Pitch Summary:
Misled investors regarding the rocket launch of 2025; the program development is far behind the company's claims; willing to sell the launch slots below stated price; overvalued;

BSD Analysis:
Rocket Lab is positioned as a second-tier launch provider after SpaceX. Bears argue that economics remain challenged in a capital-intensive, competitive industry, with launch cadence below expectations. While expansion into satellites and space systems provides diversification, profitability is distant and recurring dilution is a risk. Execution delays or launch failures could be severe catalysts.

Pitch Summary:
@maninapurpledr1 argues that ScanTech AI Systems, Inc. (STAI) is severely overlevered, unprofitable, and overvalued — with structural and governance red flags tied to Shanchun Huang, who was previously charged by the SEC for manipulative offshore trading. The author claims STAI recently borrowed money at a high 15% PIK rate and used questionable press releases — including a loan-program notification from a state (Virginia) — to hype the stock, rather than solid contracts or revenue. They warn that once recently registered shares return to float, and if the company raises equity or more investors recognize the weak fundamentals, the stock will collapse. The post notes that STAI claimed ambitious revenue targets ($26M in 2024, $475M by 2028) despite apparently negligible current assets (~$4M), heavy debt (~$35M), burning cash, and unpaid taxes. Finally, the author suggests the short-squeeze narrative may unravel when float expands. Overall, the pitch paints STAI as a high-risk speculative dump, not a credible long-term investment.

BSD Analysis:
ScanTech AI operates in a niche security-screening segment under the “Electronic Equipment, Instruments & Components” classification, offering AI-enabled CT scanning solutions for checkpoints and cargo screening. As a nano-cap company with very limited assets, negligible cash, and significant debt, STAI’s fundamental base appears extremely fragile. The alleged governance issues — namely ties to a person previously charged for market manipulation — further raise the bar for trust and credibility. Hyped press releases or speculative projections (e.g., large future revenues) carry little weight unless they convert into firm orders or contracts; in sectors like security hardware, long sales cycles and regulatory procurement processes already make revenue realization uncertain. If STAI does not secure meaningful contracts soon or fails to manage its debt, dilution via equity raises and float expansion seem likely — undermining any short-squeeze thesis or valuation optimism. Given the high risk of dilution, weak cash flows, and reputational uncertainty, STAI currently looks like a distressed small-cap with speculative upside — more a momentum/short-squeeze play than a viable long-term investment absent a material turnaround or contract wins.

Actual Post Content:
$stai is a broke, over-levered, unprofitable, overvalued company w/ direct ties to someone the SEC charged with “Manipulative Offshore Trading”. The company recently had to borrow money at 15% PIK (for Sr. Secured Debt) and has boosted its stock price with @joinyellowbrick 1/n $stai - with some questionable press releases. The stock should collapse even more when recently registered shares become available for sale, when the company raises equity and when more investors become aware of the company’s dire circumstances. @joinyellowbrick $STAI become public via a merger w/a SPAC whose Chairman & largest shareholder Shanchun Huang who in 2024 was CHARGED BY SEC FOR MANIPULATIVE STOCK TRADING (https://sec.gov/enforcement-litigation/litigation-releases/lr-25924).He was also CEO & Director of Future Fintech Group, a Nasdaq stock which has been a disaster. 3/n $stai- a hype job: stock has doubled since it issued pr that its products would be deployed" by Virginia. But pr by Virginia says equipment is only being “loaned to Virginia at no cost and w/no obligation to purchase the equipment following the 6 month pilot program.” 4/n $stai down 25% this morning. What happens when these recently registered shares become available to sell? @joinyellowbrick https://sec.gov/ix?doc=/Archives/edgar/data/0001994624/000141057825000109/tmb-20240930xs1.htm 5/n $stai - fun fact: the company added "ai" to its name when it came public, probably in an effort to dupe even more unsophisticated retail investors maninapurpledress @maninapurpledr1 · Feb 25 $stai - shorting again into this rebound pump. Doubt anyone buying this knows the co money losing co has assets of only $4mm, over $35mm of debt and desperately needs to raise equity. @joinyellowbrick maninapurpledress @maninapurpledr1 · Feb 25 Meet one of $stai largest shareholders, Shanchun Huang. The SEC already knows him so maybe you should too. I wonder if he's responsible for the recent pumping of the stock https://sec.gov/enforcement-litigation/litigation-releases/lr-25924 @joinyellowbrick maninapurpledress @maninapurpledr1 · Feb 26 Besides their deceiving press releases, the crims at $Stai said they’d generate revenue of $26 mm in 2024 and $475 mm in 2028. Guess what 2024 revenue actually was? (Hint: guess lower) @joinyellowbrick @ParrotCapital maninapurpledress @maninapurpledr1 · Feb 27 $stai same team that was charged by SEC, puts out deceptive pr, unrealistic guidance, is burning cash, had a “going concern” also didn’t pay certain federal taxes for six years!! The $6mm they owe the govt is 3x their current cash balance (and they have tons of debt too). maninapurpledress @maninapurpledr1 · Feb 27 Folks buying $stai as a short squeeze, but 0.7m shares shorted & 2.8m shares will soon be added to the float when this filing becomes effective. That should crush short squeeze and drive stock lower as 2.8 mm shares flood the market.”

URL: https://x.com/maninapurpledr1/status/1894026160780062772

Pitch Summary:
@SuicideBlonde lays out a bearish take on ONEOK’s Q4 2024 results and 2025 outlook. They argue that management is using a $227 million gain on asset sales and non-controlling interest adjustments to manufacture a headline EBITDA “beat,” while underlying EBITDA actually misses consensus by about 6%. Guidance for 2025 EBITDA is framed as underwhelming, with the midpoint slightly below street expectations. At the same time, @SuicideBlonde highlights that CAPEX guidance is ~38% above consensus despite a relatively limited set of identified major projects. The thread suggests that long lead times on these projects mean only about half of 2025 capex can be easily explained, implying questionable capital allocation or opaque spending elsewhere. Finally, the author claims leverage is being understated, noting that reported run-rate Debt/EBITDA of 3.6x only looks that low because it includes the asset-sale gain, and that a more realistic leverage figure is closer to 4.0–4.3x. Overall, the pitch frames OKE as using accounting optics and aggressive spending to present a rosier picture than the fundamentals warrant.

BSD Analysis:
From a midstream perspective, ONEOK operates in a capital-intensive segment where transparency around project economics and leverage is critical, so any perception of “EBITDA games” or optical beats can meaningfully erode investor trust. The critique that gains on asset sales are being embedded in EBITDA and leverage metrics points to lower-quality earnings and raises questions about how management frames performance versus true recurring cash generation. Within Oil & Gas Storage & Transportation, peers typically run with elevated but tightly managed leverage, so the difference between 3.6x and 4.0–4.3x Debt/EBITDA is non-trivial when thinking about ratings, cost of capital, and balance-sheet flexibility. The sharp step-up in CAPEX versus consensus, without a correspondingly robust roster of clearly articulated, high-return projects, increases the risk of value-destructive spending or poor capital discipline. Long-dated projects also introduce timing risk: investors may endure near-term FCF pressure well before seeing cash returns, and cost overruns or permitting delays are endemic to large midstream builds. If EBITDA guidance is already slightly below the street and execution stumbles, effective leverage could drift even higher, particularly in a softer commodity or NGL spread environment. On the other hand, midstream assets often have long-lived, fee-based contracts, so if projects are genuinely underpinned by strong counterparties, the ultimate earning power could still justify the capex—but the burden is on management to provide better disclosure and bridge the optics. For now, the setup described in the thread tilts the risk-reward toward skepticism until there is clearer evidence of disciplined capital allocation, more transparent metrics, and confirmation that true run-rate EBITDA supports the current spending and leverage profile.

Actual Post Content:
1/6 $OKE's Q4'24 results are disappointing primarily on account of the level of obfuscation by the company and their desire to create a "headline beat". By including a $227 million gain on sale of certain natural gas assets, $OKE is creating the impression of a large Q4 beat. 2/6 Reported Q4'24 EBITDA of $2.17 billion gives the appearance of beating Consensus by a whopping 9.2%. Yet, excluding the gain on sale ($227 mm) of assets and non-controlling interest ($77 mm), EBITDA was closer to $1.87 billion which is a 6.1% miss! 3/6 $OKE's EBITDA Guidance range for 2025 is $8.00 bn to $8.45 bn (mid-pt of $8.25 bn). The mid-point falls about 1.7% short of Consensus which stands at $8.39 bn CAPEX Guidance is for $2.8 bn to $3.2 bn which is 38% higher than Consensus at the mid-point. 4/6 $OKE's runaway CAPEX budget is way out of proportion relative to the major projects they have on hand. Their major in-progress projects are: 1) Medford Frac 2) Texas City LPG Export dock 3) Relocation of process plant from Barnett to Permian Unjustifiably high CAPEX! 5/6 The long lead-time on $OKE's major projects suggests that spending on them in 2025 will be about half the total for the year and begs the question: What on earth are they spending on? 6/6 $OKE proudly claims run-rate Debt/EBITDA of 3.6x perhaps hoping that the folks at S&P and Moody's will neglect to exclude the $227 mm of gain on asset sale from the EBITDA calculation. In truth, the run-rate Debt/EBITDA is closer to 4.3x and about 4.0x on the 2025 Guide.

URL: https://x.com/suicide95518428/status/1894178430180094275

Pitch Summary:
The author argues that Hims & Hers Health ($HIMS) faces a structurally tougher outlook following management commentary indicating an imminent switch away from compounded semaglutide toward liraglutide. Customers will be notified that semaglutide will no longer be offered, potentially driving churn to competitors that can source branded GLP-1s. Liraglutide is less effective, requires daily injections, and carries lower margins due to packaging, logistics, and likely higher CAC. Given that GLP-1s accounted for a large portion of recent revenue momentum (roughly $240m in 2024 over ~7–8 months, likely a $500–600m run-rate), the author questions how the company can achieve its 57% 2025 revenue growth guidance amid these headwinds. The concern is that non-GLP categories would need to accelerate unrealistically to offset GLP-1 pressure, making the stock vulnerable to further multiple compression after a hype-driven run.

BSD Analysis:
The direct-to-consumer telehealth market is structurally commoditized, with low switching costs, heavy customer acquisition spend, and limited product differentiation once therapies become widely available. Hims’ recent growth has been disproportionately driven by GLP-1 demand, a category now facing supply constraints, regulatory scrutiny, and margin normalization. The forced transition from semaglutide to liraglutide weakens Hims’ competitive positioning relative to peers that can source branded products, potentially impairing retention and lifetime value. While legacy categories (sexual health, dermatology, hair loss) are growing solidly, they operate in crowded markets with structurally higher CAC and lower pricing power. Cost pressures—from marketing, vertical integration into peptide manufacturing, and the loss of prior tax benefits—further compress operating leverage at a time when revenue mix is deteriorating. Valuation still embeds expectations of sustained hypergrowth despite a material change in the quality and durability of earnings. From a buy-side perspective, the risk is not near-term revenue collapse but a gradual derating as GLP-driven enthusiasm fades and the business is revalued as a lower-moat consumer healthcare platform rather than a category-defining compounder.

Actual Post Content:
$HIMS am an observer but heard on the call 1) switching from Semaglutide to Liraglutide ASAP 2) they are going to email all customers letting them know they will no longer provide Semaglutide and to find another company if want to keep getting it 3) Liraglutide is less effective and requires daily injections 4) margins for Liraglutide will be compressed because of more packaging costs and other factors (assume CaC goes up also) and 5) cannot provide actual Ozempic, Wegovy, etc because they cannot source enough but competitors can So how does this stock not just drift lower and lower? Company is just a commodity with a blow off the top chart. Before you tell me the boner pills and shampoo business grew revs 43% YoY and only $240M of 2024 revenue is from GLP-1, the hype has been around GLP-1 which was/is a temporary business - $240M is a large % of revenue for the 7 or 8 months of 2024 that they were sold for. 2025Y revenue guide is 57% growth so they are going to still need that weight loss biz to grow despite headwinds. Time to look at the $MRNA chart for clues of what happens when a new, hot business suddenly drifts - HIMS at $40 is still up 230% since GLP-1 announcement. Without SSR this would have been a lot lower today imo Contrary to I think all of FinTwit, I do believe the 2025 guide does include GLP-1. They are replacing Semaglutide with Liraglutide which both are GLP-1s but I said weight loss business originally to avoid any confusion. But on a 12 month basis, taking the 7 months of GLP revenue they would have been around $400m GLP 2024 revenue. Probably closer to $500-600m run rate now if i were to guess after time to ramp up operations and acquire customers. So if Non-GLP biz does 40% again and the GLP business does $600M in 2025 they will have met guidance. If GLP goes to $500M then they need closer to 50% growth out of non-GLP and they are then in trouble. $400M GLP, non-GLP needs 57% rev growth which feels impossible. Feels like a really hard comp and they will have to probably exceed their guides by 20-30% for the market to care in a positive way. Management obviously believes they can do it but feels like a level of skepticism is necessary given such a massive change to a large % of revenue (which market has just started to discount against). And of course they are spending more on the peptide factory, other integrations, they lose $68M of tax benefits that they got in 2024, costs are way up (1 min Superbowl commercial to produce + run is not cheap). Feel free to lmk where I am wrong because I haven't looked into $hims for years until AH today I do agree that the markets can operate irrationally as they do with $DUOL.

URL: https://x.com/OddDiligence/status/1894214480671695081

Pitch Summary:
The author argues that Brookfield Corporation ($BN) offers multiple underappreciated upside levers that collectively support a substantial valuation gap versus the current share price. Key drivers include ~20% organic growth in the annuities business, with scope to allocate up to one-third of its ~$120bn portfolio into higher-fee private products managed by Brookfield Asset Management ($BAM), amplifying fee-related earnings upstream to BN. BAM’s recent U.S. domicile is expected to facilitate S&P 500 inclusion, potentially expanding its investor base and valuation multiple. Additionally, mature infrastructure funds are approaching the phase where carried interest distributions should accelerate to BN. Finally, the author highlights ~$25bn of on-balance-sheet real estate that is implicitly valued at zero by the market despite ~4% NOI growth, with potential monetization and capital return optionality. A sum-of-the-parts valuation suggests ~$104 per share versus a current price near $58.

BSD Analysis:
The global alternative asset management industry benefits from durable secular tailwinds, including institutional demand for private credit, infrastructure, and real assets, alongside insurers’ growing appetite for yield-enhancing strategies. Brookfield’s competitive position is reinforced by scale, long-duration capital, and vertical integration across asset origination, management, and balance-sheet capital. The annuities platform represents a structurally attractive captive capital source, lowering funding costs and increasing fee-bearing AUM within BAM. Risks include capital markets cyclicality affecting realizations and carry timing, as well as execution risk in recycling balance-sheet real estate without value leakage. However, the embedded asset value and multiple avenues for capital deployment provide downside protection. Valuation implies skepticism that these assets and fee streams will be fully monetized, despite a long track record of value realization. From a buy-side perspective, BN’s appeal lies in layered optionality—fee growth, carry inflection, index inclusion, and asset monetization—offering asymmetric upside without reliance on a single catalyst.

Actual Post Content:
$bn 1/x Lot's of upside levers to pull - take your pick. 1) Annuities business growing 20% organically. Should be able to put 1/3 of the portfolio, currently $120B, into their private products, which will ramp up management fees at $bam, which $bn owns. 2/x 2) $bam just domiciled in the US, which should lead it to an SPX inclusion. 3) Have seasoned infrastructure funds that should start to kick ample carry to $bn. 3/x 4) Has $25B of on-balance sheet real estate that the market values at zero. NOI is growing at 4%. They should be monetizing this in the next few years, some of which to annuity business, and using cash to repurchase shares. 5) SOTP price is $104 vs. $58 share price.

URL: https://x.com/310value/status/1893822203159883930

Pitch Summary:
Bitcoin is positioned as a superior asset compared to gold due to its absolute scarcity, divisibility, security, and potential for yield generation. With a fixed supply cap of 21 million coins, Bitcoin is scarcer than gold, which has an uncertain final supply. Its divisibility into 100 million satoshis allows for microtransactions, unlike gold, which incurs costs when divided. Bitcoin's security is enhanced by cryptographic encryption and decentralized blockchain technology, making it resistant to fraud and seizure. As a store of value, Bitcoin is likened to 'digital gold,' offering resistance to inflation and currency devaluation. The potential for yield generation through Bitcoin lending markets further enhances its investment appeal. As Bitcoin's advantages become more recognized, its market cap is expected to grow to match that of gold, offering superior returns over the next decade.

BSD Analysis:
Bitcoin's market cap currently stands at $1.9 trillion, compared to gold's $19.8 trillion. The expectation is that as Bitcoin's properties are better understood, its market cap will increase to match gold's, resulting in a compound annual growth rate of 26.4% over the next decade. This growth is driven by Bitcoin's superior characteristics as a financial asset, including its auditability and transparency on the blockchain, which eliminates the need for estimation of value and supply. Additionally, Bitcoin's role in energy markets, where miners purchase interruptible power, contrasts with the energy demands of gold mining, highlighting Bitcoin's potential benefits to power grids. While gold may have advantages in scenarios like a grid-down event, Bitcoin's overall risk-reward profile is considered superior. As investors continue to recognize these advantages, Bitcoin is expected to significantly outperform gold as an investment.

Pitch Summary:
BFF Bank's unique business model allows it to achieve high returns on equity (ROE) of 20-40% with minimal risk of loan losses due to its government counterparty. Despite a temporary setback from regulatory asset reclassification, the bank's capital ratios are now compliant, and the dividend suspension is expected to be lifted, potentially leading to a stock re-rating.

BSD Analysis:
BFF Bank has faced a significant sell-off due to regulatory changes by the Bank of Italy, which required asset reclassification and increased capital holdings. However, the bank has already restored its capital ratios above the required limits. The suspension on dividends is likely temporary, and once lifted, the stock could re-rate to a higher price-to-book (P/B) ratio, historically not trading below 2. The bank's expansion into other European countries provides further growth opportunities. Risks include potential regulatory changes and execution challenges, but the bank's strong ROE and minimal credit cycle exposure make it a compelling investment.

Pitch Summary:
Quantum Computing Inc. (QUBT) has a history of pivots and minimal revenue, raising concerns about its legitimacy as a quantum computing company. The company has shifted from a beverage distributor to a quantum software business and now claims to focus on quantum computing hardware. Recent plans to establish a quantum photonic chip foundry amid semiconductor hype further question its credibility. Reports of non-existent facilities and faked revenues suggest that QUBT may not be a viable investment. Given its minimal revenues and questionable history, QUBT is not considered a potential investment.

BSD Analysis:
Quantum Computing Inc.'s track record of pivots and minimal revenue generation raises significant red flags for investors. The company's recent focus on quantum photonic chips appears opportunistic, capitalizing on industry hype without substantial backing. Reports of non-existent facilities and dubious revenue claims further undermine its credibility. The lack of transparency and consistent business strategy suggests that QUBT may not have a sustainable business model. Investors should exercise caution, as the company's history and current operations do not inspire confidence in its ability to succeed in the competitive quantum computing industry.

Pitch Summary:
D-Wave Quantum is known for its quantum annealers, which are designed to solve large optimization problems. The company has commercialized its offerings and generates revenue from cloud-based quantum computing access. Despite being the first pure-play quantum computing company to commercialize its products, QBTS's stock trades at high multiples, reflecting significant growth expectations. The company's focus on a niche market and the uncertainty surrounding the broader adoption of quantum computing technologies contribute to the risk. The recent equity raise and the high valuation suggest that the market may have already priced in much of the potential growth.

BSD Analysis:
D-Wave Quantum's focus on quantum annealers positions it uniquely within the quantum computing industry. However, the niche nature of its technology and the high valuation multiples present challenges. The company's ability to capture a significant portion of the optimization market will be crucial for its growth prospects. The recent equity raise indicates a need for capital, which may dilute existing shareholders. Additionally, the competitive landscape and the evolving nature of quantum computing technologies add to the uncertainty. While D-Wave Quantum has commercialized its offerings, the high valuation and market expectations suggest caution.

Pitch Summary:
IONQ is a leading player in the quantum computing industry, utilizing trapped-ion technology for its quantum computers. The company has seen significant revenue growth, driven by government contracts, and maintains a strong cash position. However, the stock is trading at high revenue multiples, suggesting that substantial growth is already priced in. Management's ambitious revenue target of $1 billion by 2030 implies a high CAGR, but the competitive and nascent nature of the industry introduces uncertainty. The current valuation appears generous, given the early stage of quantum computing and the challenges in achieving commercial-scale applications.

BSD Analysis:
IONQ's strong cash position and revenue growth from government contracts highlight its potential in the quantum computing space. However, the high valuation multiples reflect market optimism that may not be sustainable given the industry's infancy. The company's ambitious revenue targets suggest significant growth potential, but achieving these targets will depend on the broader adoption of quantum computing and IONQ's ability to maintain its competitive edge. The uncertainty surrounding the dominant quantum computing approach and the competitive landscape further complicates the investment thesis. Overall, while IONQ is well-positioned, the current stock price may not offer a sufficient margin of safety.